Bei Tan1,2, Jyh-Chin Yang3, Carol L Young4, Shrinivas Bishu2, Stephanie Y Owyang2, Mohamad El-Zaatari2, Min Zhang2, Helmut Grasberger2, Jia-Ming Qian1, John Y Kao5. 1. Department of Gastroenterology, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China. 2. Division of Gastroenterology, Department of Internal Medicine, Michigan Medicine, University of Michigan, 6520A MSRB1, SPC 5682, 1150 West Medical Center Drive, Ann Arbor, MI, 48109, USA. 3. Division of Gastroenterology, Department of Internal Medicine, Hospital and College of Medicine, National Taiwan University, Taipei, Taiwan. 4. Clinical Microbiology Laboratory, Department of Pathology, Michigan Medicine, University of Michigan, Ann Arbor, MI, USA. 5. Division of Gastroenterology, Department of Internal Medicine, Michigan Medicine, University of Michigan, 6520A MSRB1, SPC 5682, 1150 West Medical Center Drive, Ann Arbor, MI, 48109, USA. jykao@umich.edu.
Abstract
BACKGROUND: The current practice guidelines recommend that Helicobacter pylori (H. pylori) culture and antimicrobial susceptibility testing (AST) be considered after patients failed the second course of H. pylori eradication therapy. AIMS: Here we report the real life experience of following this recommendation in the USA. METHODS: We established an in-house H. pylori culture protocol for AST and identified retrospectively patients who previously failed ≥ 2 courses of anti-H. pylori therapy and underwent esophagogastroduodenoscopy with AST at University of Michigan from 2010 to 2017. We determined the rate of H. pylori antibiotic resistance, the success rates of AST-guided tailored therapy, and the risk factors associated with treatment failure. RESULTS: Forty-seven patients were identified and 34 (72.3%) had successful cultures and AST. The most common antibiotic resistance was to metronidazole (79.4%), followed by clarithromycin (70.6%) and ciprofloxacin (42.9%). None of the patients were resistant to amoxicillin or tetracycline. The overall success rate of AST-guided tailored therapy was low (44.4%, 12/27). In patients infected with metronidazole-resistant H. pylori, bismuth quadruple therapy appears to be superior compared to non-bismuth quadruple therapy (6/8 or 75.0% vs. 3/14 or 21.4%, P = 0.03). High body mass index was significantly associated with tailored therapy failure (OR 1.24, 95% CI 1.00-1.54, P = 0.049). CONCLUSIONS: The success rate of AST-guided salvage therapy in the USA is low particularly in those with high BMI. Bismuth-based therapy appears to be better than non-bismuth-based regimens.
BACKGROUND: The current practice guidelines recommend that Helicobacter pylori (H. pylori) culture and antimicrobial susceptibility testing (AST) be considered after patients failed the second course of H. pylori eradication therapy. AIMS: Here we report the real life experience of following this recommendation in the USA. METHODS: We established an in-house H. pylori culture protocol for AST and identified retrospectively patients who previously failed ≥ 2 courses of anti-H. pylori therapy and underwent esophagogastroduodenoscopy with AST at University of Michigan from 2010 to 2017. We determined the rate of H. pylori antibiotic resistance, the success rates of AST-guided tailored therapy, and the risk factors associated with treatment failure. RESULTS: Forty-seven patients were identified and 34 (72.3%) had successful cultures and AST. The most common antibiotic resistance was to metronidazole (79.4%), followed by clarithromycin (70.6%) and ciprofloxacin (42.9%). None of the patients were resistant to amoxicillin or tetracycline. The overall success rate of AST-guided tailored therapy was low (44.4%, 12/27). In patients infected with metronidazole-resistant H. pylori, bismuth quadruple therapy appears to be superior compared to non-bismuth quadruple therapy (6/8 or 75.0% vs. 3/14 or 21.4%, P = 0.03). High body mass index was significantly associated with tailored therapy failure (OR 1.24, 95% CI 1.00-1.54, P = 0.049). CONCLUSIONS: The success rate of AST-guided salvage therapy in the USA is low particularly in those with high BMI. Bismuth-based therapy appears to be better than non-bismuth-based regimens.
Authors: Yuan Wenzhen; Li Yumin; Guan Quanlin; Yang Kehu; Jiang Lei; Wang Donghai; Yang Lijuan Journal: Intern Med Date: 2010-06-15 Impact factor: 1.271
Authors: Adrienne H Tveit; Michael G Bruce; Dana L Bruden; Julie Morris; Alisa Reasonover; Debby A Hurlburt; Thomas W Hennessy; Brian McMahon Journal: J Clin Microbiol Date: 2011-08-03 Impact factor: 5.948
Authors: P Malfertheiner; F Megraud; C A O'Morain; J P Gisbert; E J Kuipers; A T Axon; F Bazzoli; A Gasbarrini; J Atherton; D Y Graham; R Hunt; P Moayyedi; T Rokkas; M Rugge; M Selgrad; S Suerbaum; K Sugano; E M El-Omar Journal: Gut Date: 2016-10-05 Impact factor: 23.059
Authors: Kai-feng Pan; Lian Zhang; Markus Gerhard; Jun-ling Ma; Wei-dong Liu; Kurt Ulm; Jian-xi Wang; Lei Zhang; Yang Zhang; Monther Bajbouj; Lan-fu Zhang; Ming Li; Michael Vieth; Rui-yong Liu; Michael Quante; Le-hua Wang; Stepan Suchanek; Tong Zhou; Wei-xiang Guan; Roland Schmid; Meinhard Classen; Wei-cheng You Journal: Gut Date: 2015-05-18 Impact factor: 23.059
Authors: Tiankuo Yang; Renwei Hu; Xiaoqiong Tang; Yalin Shen; Alfred Tay; Xuenan Pi; Gang Wang; Aleksandra W Debowski; Keith A Stubbs; Mohammed Benghezal; Barry J Marshall; Hong Li; Hong Tang Journal: Precis Clin Med Date: 2020-03-17
Authors: Candace Goodman; Katrina N Lyon; Aitana Scotto; Cyra Smith; Thomas A Sebrell; Andrew B Gentry; Ganesh Bala; Gary D Stoner; Diane Bimczok Journal: Antibiotics (Basel) Date: 2021-07-12